Avalo Therapeutics (NASDAQ:AVTX) Upgraded at Wedbush

Avalo Therapeutics (NASDAQ:AVTX) was upgraded by Wedbush to a “strong-buy” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other equities research analysts also recently commented on AVTX. BTIG Research began coverage on Avalo Therapeutics in a report on Thursday, December 19th. They set a “buy” rating and a $40.00 price objective for the company. HC Wainwright started coverage on Avalo Therapeutics in a research report on Thursday, October 24th. They set a “neutral” rating on the stock.

Avalo Therapeutics Stock Performance

NASDAQ AVTX opened at $8.44 on Thursday. Avalo Therapeutics has a 52 week low of $4.20 and a 52 week high of $34.46. The business has a 50 day moving average price of $7.82 and a 200-day moving average price of $9.40.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its position in Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company’s stock worth $31,000 after purchasing an additional 3,754 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at $145,000. Northern Trust Corp purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at $168,000. Finally, Bank of Montreal Can purchased a new position in shares of Avalo Therapeutics during the 4th quarter valued at $446,000. Hedge funds and other institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.